BNTX - BioNTech SE
NASDAQ
->
Healthcare
->
Biotechnology
Mainz,
Germany
Type: Equity
BNTX price evolution
BNTX
| (in millions $) | 5 Aug 2024 | 30 Jul 2024 | 20 Mar 2024 | 6 Nov 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10861.91 | $10376.7 | $12591.78 | $13943.45 |
| Short term investments | $7839.18 | $5775.91 | $2929.65 | |
| Net receivables | $79.34 | $286.5 | $2327.23 | $2068.41 |
| Inventory | $356 | $340.1 | $386.16 | $429.49 |
| Total current assets | $19136.44 | $18281.6 | $21081.08 | $19371 |
| Long term investments | $4141.29 | $3755.82 | $3572.8 | |
| Property, plant & equipment | $909.22 | $1125 | $817.45 | $753.08 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $23277.73 | $22237.9 | $24836.91 | $22943.8 |
| Current liabilities | ||||
| Accounts payable | $922.72 | $881.5 | $382.17 | $230.09 |
| Deferred revenue | ||||
| Short long term debt | $36.95 | $30.34 | $41.33 | |
| Total current liabilities | $2539.33 | $2425.9 | $2235.25 | $1867.14 |
| Long term debt | $229.55 | $219.3 | $206.2 | $167.27 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $3313.62 | $3165.6 | $2980.04 | $2418.03 |
| Shareholders' equity | ||||
| Retained earnings | $19512.02 | $18834.5 | $21335.86 | $19945.75 |
| Other shareholder equity | ||||
| Total shareholder equity | $19964.11 | $21856.86 | $20525.77 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Mar 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11663.7 | $13875.1 | $1715.46 | $1210.21 |
| Short term investments | $5775.91 | $483.6 | $502.06 | $137.23 |
| Net receivables | $2339.7 | $7146 | $12548.2 | $166.37 |
| Inventory | $357.7 | $439.6 | $509.26 | $64.12 |
| Total current assets | $19527.3 | $21922 | $15274.98 | $1666.9 |
| Long term investments | $3755.82 | $1421.48 | $768.7 | |
| Property, plant & equipment | $971.6 | $821.1 | $326.84 | $325.96 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $744.46 | |||
| Total investments | ||||
| Total assets | $23006.3 | $23279.1 | $16043.68 | $2318.62 |
| Current liabilities | ||||
| Accounts payable | $354 | $204.1 | $162.15 | $102.29 |
| Deferred revenue | ||||
| Short long term debt | $30.34 | $37.71 | $131.65 | $3.02 |
| Total current liabilities | $2070.5 | $2950.6 | $3528.42 | $606.01 |
| Long term debt | $191 | $176.2 | $173.91 | $153.02 |
| Total noncurrent liabilities | $389.25 | |||
| Total debt | $293.41 | |||
| Total liabilities | $2760.4 | $3223.5 | $3990.04 | $946.77 |
| Shareholders' equity | ||||
| Retained earnings | $20008.1 | $19812.3 | $10015.8 | -$409.63 |
| Other shareholder equity | $1768.3 | $1539.95 | ||
| Total shareholder equity | $21856.86 | $21007.08 | $12053.64 | $1371.85 |
| (in millions $) | 5 Aug 2024 | 30 Jul 2024 | 20 Mar 2024 | 6 Nov 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $134.72 | $128.7 | $1660.23 | $925 |
| Cost of revenue | $62.6 | $205.22 | $167.17 | |
| Gross Profit | $72.12 | $68.9 | $1455 | $757.83 |
| Operating activities | ||||
| Research & development | $611.94 | $658.58 | $514.42 | |
| Selling, general & administrative | $192.39 | $148.33 | $164.17 | |
| Total operating expenses | $867.76 | $1035.1 | $1024.65 | $845.75 |
| Operating income | -$733.05 | $635.58 | $79.24 | |
| Income from continuing operations | ||||
| EBIT | -$733.05 | $635.58 | $79.24 | |
| Income tax expense | $2.09 | $2 | $223.79 | $69.02 |
| Interest expense | $160.4 | |||
| Net income | ||||
| Net income | -$845.57 | -$807.8 | $505.82 | $165.93 |
| Income (for common shares) | -$845.57 | $505.82 | $165.93 | |
| (in millions $) | 31 Jan 2024 | 27 Mar 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3819 | $18131.85 | $482.32 | |
| Cost of revenue | $3137.09 | $704.36 | ||
| Gross Profit | $3219.2 | $14994.76 | -$222.04 | |
| Operating activities | ||||
| Research & development | $1609.92 | |||
| Selling, general & administrative | $570.02 | $107.22 | ||
| Total operating expenses | $2311.2 | $5743.34 | $808.13 | |
| Operating income | $12388.52 | -$325.8 | ||
| Income from continuing operations | ||||
| EBIT | $12388.52 | -$325.8 | ||
| Income tax expense | $255.8 | $3686.68 | -$161 | |
| Interest expense | $313.5 | -$2 | ||
| Net income | ||||
| Net income | $930.3 | $9881.99 | $15.2 | |
| Income (for common shares) | $9881.99 | $15.2 | ||
| (in millions $) | 5 Aug 2024 | 30 Jul 2024 | 20 Mar 2024 | 6 Nov 2023 |
|---|---|---|---|---|
| Net income | -$845.57 | $505.82 | $165.93 | |
| Operating activities | ||||
| Depreciation | $51.93 | $89.92 | $40.87 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $1705.78 | $1128.36 | $732.89 | |
| Investing activities | ||||
| Capital expenditures | -$146.83 | -$229.32 | -$145.06 | |
| Investments | ||||
| Total cash flows from investing | -$234.55 | -$2545.8 | -$3107.19 | -$1187.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$18434.59 | -$18131.16 | -$16664.5 | |
| Total cash flows from financing | -$23.91 | -$30.7 | -$49.46 | -$308.42 |
| Effect of exchange rate | -$20.4 | |||
| Change in cash and equivalents | $10861.91 | -$1287 | $12591.78 | $13943.45 |
| (in millions $) | 31 Jan 2024 | 27 Mar 2023 | 30 Mar 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $9881.99 | $10477.47 | $15.2 | |
| Operating activities | ||||
| Depreciation | $129.15 | $76.55 | $38.74 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $14221.54 | $905.69 | -$13.47 | |
| Investing activities | ||||
| Capital expenditures | -$380.54 | -$156.77 | -$66.03 | |
| Investments | ||||
| Total cash flows from investing | -$6954.5 | -$36.97 | -$576.27 | -$144.85 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$14794.7 | -$1920.51 | $141.72 | |
| Total cash flows from financing | -$778.6 | -$1486.63 | $95.89 | $894.73 |
| Effect of exchange rate | $150.3 | -$45.34 | ||
| Change in cash and equivalents | -$2211.4 | $12663.78 | $384.53 | $691.06 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $2.85B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$981.63M |
| Revenue Q/Q | -24.32% |
| Revenue Y/Y | -65.54% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -4.21% |
| ROE | N/A |
| Debt/Equity | 0.13 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.54 |
| Quick ratio | 7.40 |